Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature

SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2...

Descripción completa

Detalles Bibliográficos
Autores principales: Tepasse, Phil‐Robin, Hafezi, Wali, Lutz, Mathias, Kühn, Joachim, Wilms, Christian, Wiewrodt, Rainer, Sackarnd, Jan, Keller, Martin, Schmidt, Hartmut H., Vollenberg, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300950/
https://www.ncbi.nlm.nih.gov/pubmed/32557623
http://dx.doi.org/10.1111/bjh.16896
Descripción
Sumario:SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2 viraemia with fatal outcome in patients after rituximab therapy.

Ejemplares similares